15.33

0.06% 0.03

Myriad Genetics Inc (MYGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MYGN? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$15.30

Offen:

$15.33

24-Stunden-Volumen:

124.99K

Relative Volume:

0.17

Marktkapitalisierung:

$1.36B

Einnahmen:

$802.20M

Nettoeinkommen (Verlust:

$-155.20M

KGV:

-4.5625

EPS:

-3.36

Netto-Cashflow:

$-141.30M

1W Leistung:

-2.37%

1M Leistung:

-32.08%

6M Leistung:

-37.21%

1J Leistung:

-12.42%

1-Tages-Spanne:

$15.21

$15.61

1-Wochen-Bereich:

$14.72

$15.80

52-Wochen-Spanne:

$14.72

$29.30

Myriad Genetics Inc Stock (MYGN) Company Profile

Firmenname

Myriad Genetics Inc

Sektor

Healthcare (1195)

Branche

Diagnostics & Research (57)

Telefon

801-584-3600

Adresse

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Mitarbeiter

2,700

Twitter

@myriadgenetics

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

MYGN's Discussions on Twitter

Vergleichen Sie MYGN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MYGN	15.32	1.36B	802.20M	-155.20M	-141.30M	-3.36
TMO	509.68	195.55B	42.37B	6.14B	7.78B	15.26
DHR	231.52	166.92B	23.74B	3.89B	4.98B	7.93
A	131.20	36.94B	6.50B	1.41B	1.42B	3.82
IQV	194.83	35.03B	15.32B	1.41B	1.96B	5.95
IDXX	412.39	33.80B	3.84B	866.24M	792.60M	9.80

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-21	Fortgesetzt	Piper Sandler	Neutral
2023-12-19	Eingeleitet	Wells Fargo	Equal Weight
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-07-05	Fortgesetzt	JP Morgan	Underweight
2023-05-23	Hochstufung	Goldman	Sell → Buy
2023-01-18	Hochstufung	Raymond James	Mkt Perform → Outperform
2022-10-06	Eingeleitet	Stephens	Equal-Weight
2021-10-15	Fortgesetzt	Cowen	Market Perform
2021-06-15	Eingeleitet	Raymond James	Mkt Perform
2021-06-03	Eingeleitet	Goldman	Sell
2019-09-26	Herabstufung	BofA/Merrill	Neutral → Underperform
2019-08-14	Herabstufung	Piper Jaffray	Overweight → Neutral
2019-08-02	Hochstufung	BofA/Merrill	Underperform → Neutral
2019-08-01	Hochstufung	Barclays	Underweight → Equal Weight
2019-07-29	Herabstufung	Needham	Strong Buy → Hold
2019-07-09	Herabstufung	Cowen	Outperform → Market Perform
2019-03-12	Bestätigt	Needham	Strong Buy
2019-01-03	Eingeleitet	Needham	Strong Buy
2018-11-30	Hochstufung	Goldman	Sell → Neutral
2018-10-10	Hochstufung	Piper Jaffray	Neutral → Overweight
2018-07-11	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2018-03-21	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2018-01-29	Eingeleitet	Goldman	Sell
2018-01-22	Bestätigt	Barclays	Equal Weight
2018-01-05	Eingeleitet	BTIG Research	Buy
2017-10-02	Fortgesetzt	Leerink Partners	Mkt Perform
2017-08-09	Bestätigt	Barclays	Equal Weight
2017-02-08	Hochstufung	Ladenburg Thalmann	Sell → Neutral
2017-01-18	Eingeleitet	Deutsche Bank	Sell
2016-10-10	Herabstufung	Ladenburg Thalmann	Neutral → Sell

Alle ansehen

Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten

06:30 AM

Clinical Oncology Next Generation Sequencing (NGS) Market - openPR

06:30 AM

Nov 20, 2024

Myriad Genetics Announces Incorporation of its Proprietary - GlobeNewswire

Nov 20, 2024

Myriad Genetics Expands Illumina Partnership, Integrates Key Cancer Testing Technology | MYGN Stock News - StockTitan

Nov 20, 2024

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores - MSN

Nov 20, 2024

Myriad Genetics (NASDAQ:MYGN) Downgraded to "Hold" Rating by StockNews.com - MarketBeat

Nov 20, 2024

Breast Cancer Screening and Diagnostic Techniques Market - openPR

Nov 20, 2024

Nov 19, 2024

Myriad Genetics (NASDAQ:MYGN) Reaches New 1-Year Low After Analyst Downgrade - MarketBeat

Nov 19, 2024

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy - GlobeNewswire

Nov 19, 2024

Myriad Genetics Launches Industry's First 8-Week Prenatal DNA Screen | MYGN Stock News - StockTitan

Nov 19, 2024

Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley - Yahoo Finance

Nov 19, 2024

SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer - GlobeNewswire Inc.

Nov 19, 2024

Nov 18, 2024

Morgan Stanley Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat

Nov 18, 2024

State of New Jersey Common Pension Fund D Acquires New Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Nov 18, 2024

Nov 17, 2024

MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire

Nov 17, 2024

Nov 15, 2024

Simplify Asset Management Inc. Buys Shares of 173,626 Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Nov 15, 2024

Nov 14, 2024

Predictive Genetic Testing & Consumer/Wellness Genomics - GlobeNewswire

Nov 14, 2024

Nov 13, 2024

Long Term Trading Analysis for (MYGN) - Stock Traders Daily

Nov 13, 2024

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch - The Manila Times

Nov 13, 2024

Minimal Residual Disease Testing Market Share, Growth Drivers, - openPR

Nov 13, 2024

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St

Nov 13, 2024

Myriad Genetics stock hits 52-week low at $16.6 amid market shifts - Investing.com Australia

Nov 13, 2024

Nov 12, 2024